August 12, 2025 — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced promising progress in its ARTEMIS Phase 3 trial, driven by strong enthusiasm for its potential One And Done™ therapy for wet AMD. Enrollment is expected to be completed in 1Q 2026, with topline data anticipated in 1H 2027. The company also reported financial results for the second quarter of 2025 and announced a $10 million private placement with Frazier Life Sciences.
Long-term follow-up data from the LUNA Phase 2 study is expected to be presented in the fourth quarter of 2025.
Cash, cash equivalents, and short-term investments were $44.4 million as of June 30, 2025. Research and development expenses were $37.1 million for the three months ended June 30, 2025, while general and administrative expenses were $12.7 million for the same period.
Net loss was $49.2 million, or $2.34 per basic and diluted share, for the three months ended June 30, 2025.
Jason Awe, Ph.D.
Executive Director, Corporate Communications
jawe@adverum.com
Source: Adverum Biotechnologies
